Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
← catalyst calendarNCT07232030 · readout ≤ 2,357 d
Sponsored by CVRx, Inc. (industry) · CVRX — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
2,500estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-24 | actual | When the study began enrolling |
| Primary completion | Jan 2033 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Heart Failure
- Heart Failure NYHA Class II
- Heart Failure NYHA Class III
Interventions
- Device: Barostim System
- Other: Usual care medical management
Primary outcomes
what the primary-completion date above is the date OFPrimary Effectiveness Endpoint
measured Through 24-months follow-up
Primary Safety Endpoint
measured Within 180 days of the device implant
Permalink · CVRX's whole pipeline · Catalyst calendar · Every registered study · What changed